Pieris Pharmaceuticals In... (PIRS)
NASDAQ: PIRS
· Real-Time Price · USD
13.60
-2.51 (-15.58%)
At close: Dec 13, 2024, 10:00 PM
Pieris Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -20.73M | -17.43M | -15.95M | -23.82M | -16.25M | -24.54M | -28.06M | -27.05M | -41.36M | -33.28M | -34.71M | -41.51M | -46.67M | -45.74M | -50.61M | -48.35M | -37.8M |
Depreciation & Amortization | 30K | n/a | -228K | 480K | 1.21M | 1.81M | 2.59M | 2.65M | 2.51M | 2.78M | 2.78M | 2.6M | 2.61M | 2.37M | 2.39M | 2.3M | 2.19M |
Stock-Based Compensation | 1.45M | 830K | 1.67M | 2.31M | 2.94M | 3.35M | 3.85M | 3.85M | 4.11M | 4.4M | 4.77M | 5.17M | 5.19M | 5.21M | 5.07M | 5.09M | 5.01M |
Other Working Capital | 3.41M | n/a | 21.67M | 4.38M | -16.71M | -12.71M | -32.97M | -17.9M | -6.3M | -26.84M | -17.96M | -17.46M | 33.29M | 43.48M | 32.17M | 37.57M | -12.68M |
Other Non-Cash Items | 4.35M | 6.18M | 1.51M | 559K | 880K | -824K | -460K | -778K | -473K | -507K | -179K | 198K | 102K | -30K | 649K | -27K | 189K |
Deferred Income Tax | n/a | n/a | -253K | 14.64M | 14.53M | 14.53M | 14.79M | -106K | n/a | n/a | n/a | n/a | n/a | n/a | 164K | 164K | 164K |
Change in Working Capital | 3.96M | n/a | -14.34M | -31.63M | -52.71M | -48.14M | -39.78M | -24.72M | -13.11M | -33.37M | -30.65M | -30.15M | 20.6M | 30.52M | 32.2M | 37.61M | -12.65M |
Operating Cash Flow | -10.61M | -10.84M | -28M | -37.87M | -49.82M | -53.82M | -47.08M | -46.14M | -48.28M | -59.93M | -57.94M | -63.65M | -18.16M | -7.66M | -10.13M | -3.22M | -42.9M |
Capital Expenditures | n/a | n/a | 13K | -56K | -123K | -171K | -1.19M | -1.16M | -1.72M | -2.06M | -1.39M | -1.71M | -1.31M | -949K | -1.19M | 5K | -827K |
Cash Acquisitions | n/a | n/a | -3.44M | -1.52M | -222K | -12.17M | -8.74M | -16.16M | -17.45M | -5.5M | -5.5M | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | -7.57M | -14.59M | -21.29M | -22.84M | -20.47M | -24.99M | -33.38M | -48.4M | -43.19M | -31.64M | -16.56M | n/a | -321K | -2.97M | -15.47M |
Sales Maturities Of Investments | -9M | n/a | 20M | 27.29M | 30.51M | 35.01M | 30.31M | 42.24M | 41.7M | 28.2M | 21.9M | 4.85M | n/a | n/a | 15.75M | 35.91M | 55.06M |
Other Investing Acitivies | 2.18M | 11.18M | 16.93M | 12.7M | 9.22M | 12.17M | 9.76M | 17.17M | 8.24M | -20.27M | -21.29M | -26.8M | -16.56M | n/a | 15.43M | 32.94M | 39.6M |
Investing Cash Flow | -9M | n/a | 14.77M | 12.64M | 9.1M | 12M | 9.66M | 17.11M | 7.62M | -21.24M | -22.68M | -28.5M | -17.87M | -949K | 14.24M | 32.95M | 38.77M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.73M | -1.73M | -1.73M |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 85.89M | 87.09M | 14K | 14K | 66K | 66K | 145K | 145K | 207K | 292K | 434K | 1M | 2.09M | 2.03M | 1.87M | 1.3M | 511K |
Financial Cash Flow | 85.89M | 87.09M | 14K | 14K | 19.8M | 19.8M | 19.87M | 20.16M | 656K | 7.21M | 12.02M | 33.66M | 55.99M | 59.13M | 54.3M | 42.01M | 19.81M |
Net Cash Flow | 56.54M | 66.21M | -13.53M | -25.21M | -20.66M | -21.24M | -15.53M | -9.32M | -43.99M | -79.13M | -76.63M | -64.84M | 16.9M | 47.33M | 58.16M | 74.8M | 19.4M |
Free Cash Flow | -10.61M | -10.84M | -27.99M | -37.92M | -49.94M | -53.99M | -48.27M | -47.29M | -50M | -61.99M | -59.34M | -65.36M | -19.48M | -8.61M | -11.32M | -3.21M | -43.73M |